Recent Company News

• 04:34 PM ET Jun 28, 2026
  

  BridgeBio Pharma reports positive results from PROPEL 3 study presented at ICCBH and simultaneously published in NEJM ($70.24, 0.00)

• 02:22 AM ET Jun 24, 2026
  

  Kyowa Kirin's KK8398 - infigratinib obtains Japan MHLW orphan drug designation for pediatric patients with chondrodysplasia (¥2545.0000, +41)

• 12:09 PM ET Mar 29, 2026
  

  Bristol Myers Squibb presents, publishes data from SCOUT-HCM trial of Camzyos ($58.54, 0.00)

• 08:59 AM ET Mar 23, 2026
  

  Tarsus TP-03 0.25% approval in China for the treatment of Demodex Blepharitis triggers $15M milestone payment ($64.51, 0.00)